Literature DB >> 21111871

Clinical outcomes of nitinol and stainless steel uncovered metal stents for malignant biliary strictures: is there a difference?

Brian R Weston1, William A Ross, Jun Liu, Jeffrey H Lee.   

Abstract

BACKGROUND: Self-expandable metal stents (SEMSs) made from nitinol (N) were developed as a potentially more effective alternative to conventional stainless steel (SS) stents.
OBJECTIVE: To compare clinical outcomes of N versus SS stents in the management of malignant biliary strictures.
DESIGN: Retrospective study.
SETTING: Tertiary-care cancer center. PATIENTS: All patients with first-time N (Flexxus) and SS (Wallstent) uncovered biliary SEMSs placed between January 2006 and October 2007.
INTERVENTIONS: SEMS placement.
RESULTS: A total of 81 N and 96 SS stents were placed. The most common cancer diagnosis was pancreatic (80.2% N; 62.5% SS; P = .06). The most frequent site of stricture was the common bile duct (85.2% N; 86.5% SS; P = .31). Biliary decompression was achieved in 93.8% of the N group and 86.4% of the SS group (P = .22). Immediate stent manipulation was required in 4 patients in each group. Subsequent intervention for poor drainage was performed in 17 N (21%) and 26 SS (27%) stents at mean times of 142.1 days (range, 5-541 days; median, 77 days) and 148.1 days (range, 14-375; median, 158.5), respectively (P = .17). The occlusion rate between N and SS stents was not significant (P = .42). The overall durations of stent patency in the N and SS group were similar (median 129 and 137 days, respectively; P = .61), including the subgroup analysis performed on patients with pancreatic cancer (P = .60) and common duct strictures (P = .77). Complication rates were low in both groups (early: 3.7% N, 6.3% SS; late: 2.5% N, 3.1% SS). Ninety percent underwent chemotherapy and 38% radiation therapy in each group. LIMITATIONS: Retrospective design.
CONCLUSION: Similar outcomes were achieved with N and SS stents regarding efficacy, duration of stent patency, occlusion rates, and complications. Our results are most applicable to patients with common duct strictures and pancreatic cancer.
Copyright © 2010 American Society for Gastrointestinal Endoscopy. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21111871     DOI: 10.1016/j.gie.2010.08.035

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  4 in total

1.  Risk factors for pancreatitis following transpapillary self-expandable metal stent placement.

Authors:  Kazumichi Kawakubo; Hiroyuki Isayama; Yousuke Nakai; Osamu Togawa; Naoki Sasahira; Hirofumi Kogure; Takashi Sasaki; Saburo Matsubara; Natsuyo Yamamoto; Kenji Hirano; Takeshi Tsujino; Nobuo Toda; Minoru Tada; Masao Omata; Kazuhiko Koike
Journal:  Surg Endosc       Date:  2011-10-20       Impact factor: 4.584

2.  Efficacy and safety of covered self-expandable metal stents for management of distal malignant biliary obstruction due to lymph node metastases.

Authors:  Kazumichi Kawakubo; Hiroyuki Isayama; Yousuke Nakai; Osamu Togawa; Naoki Sasahira; Hirofumi Kogure; Takashi Sasaki; Saburo Matsubara; Natsuyo Yamamoto; Kenji Hirano; Takeshi Tsujino; Nobuo Toda; Minoru Tada; Masao Omata; Kazuhiko Koike
Journal:  Surg Endosc       Date:  2011-04-13       Impact factor: 4.584

3.  How to design the optimal self-expandable oesophageal metallic stents: 22 years of experience in 645 patients with malignant strictures.

Authors:  Han Kyu Na; Ho-Young Song; Jin Hyoung Kim; Jung-Hoon Park; Min Kyoung Kang; Jongjin Lee; Se Jin Oh
Journal:  Eur Radiol       Date:  2012-09-27       Impact factor: 5.315

4.  Partially covered metal stents have longer patency than uncovered and fully covered metal stents in the management of distal malignant biliary obstruction: a retrospective study.

Authors:  Yudai Yokota; Mitsuharu Fukasawa; Shinichi Takano; Makoto Kadokura; Hiroko Shindo; Ei Takahashi; Sumio Hirose; Satoshi Kawakami; Yoshimitsu Fukasawa; Tadashi Sato; Nobuyuki Enomoto
Journal:  BMC Gastroenterol       Date:  2017-10-11       Impact factor: 3.067

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.